Anti-CTLA-4 and BRAF inhibition in patients with metastatic melanoma and brain metastases Journal Article
| Authors: | Puzanov, I.; Wolchok, J. D.; Ascierto, P. A.; Hamid, O.; Margolin, K. |
| Article Title: | Anti-CTLA-4 and BRAF inhibition in patients with metastatic melanoma and brain metastases |
| Abstract: | Until recently, there were few treatment options for patients with advanced or metastatic melanoma associated with significant increases in overall survival. Of these, patients with disease that has metastasized to the brain have a particularly poor prognosis and generally ineffective treatment options. Recent advances in immuno-oncology have led to the approval of ipilimumab, an antibody that blocks cytotoxic T-lymphocyte antigen-4 to augment antitumour T-cell responses, and vemurafenib, a BRAF kinase inhibitor. These agents, along with others on the horizon, are promising treatment options for patients with melanoma and CNS involvement. Here we review the data generated to date in patients with melanoma and brain metastases and suggest the direction that future studies may take to optimize outcomes in this subpopulation of patients. © 2013 Informa UK Ltd. |
| Keywords: | cancer survival; treatment response; overall survival; thalidomide; review; squamous cell carcinoma; placebo; cancer combination chemotherapy; drug efficacy; drug safety; drug withdrawal; temozolomide; outcome assessment; dacarbazine; glycoprotein gp 100; ipilimumab; melanoma; progression free survival; liver toxicity; tumor volume; bleeding; gastrointestinal symptom; neuropathy; antineoplastic activity; mutational analysis; drug dose escalation; fever; cancer inhibition; whole body radiation; adverse outcome; drug mechanism; blood brain barrier; brain metastasis; nausea and vomiting; colitis; liver disease; skin disease; seizure; headache; stereotactic radiosurgery; cytotoxic t lymphocyte antigen 4; digestive system perforation; b raf kinase; brain hemorrhage; endocrine disease; bone marrow toxicity; brain metastases; braf gene; fotemustine; metastatic melanoma; hypophysitis; vemurafenib; cancer prognosis; dabrafenib |
| Journal Title: | Expert Review of Dermatology |
| Volume: | 8 |
| Issue: | 5 |
| ISSN: | 1746-9872 |
| Publisher: | Informa Healthcare |
| Date Published: | 2013-10-01 |
| Start Page: | 479 |
| End Page: | 487 |
| Language: | English |
| DOI: | 10.1586/17469872.2013.835922 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | --- - "Export Date: 2 December 2013" - "Source: Scopus" |
